DOCSLIB.ORG

Manipulating the Local Nerve Environment Through Targeted

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Manipulating the Local Nerve Environment Through Targeted A L Z A SPECIAL DELIVERY ® VOLUME 18, NO. 1 ALZA CORPORATION LORRI PERKINS, EDITOR MARCH 1996 Manipulating the Local L-NAME Elucidates the Role of Nitric Nerve Environment through Oxide Targeted Delivery Nitric oxide (NO) is a free-radical gas that acts as a vasodilator. It is derived from L-arginine in endothe- Targeted delivery is especially stumps of a sectioned sciatic nerve lial cells, macrophages, neutrophils, useful when the desired drug effect is and to guide regeneration (Figure 1). platelets, and neurons. A shortage dependent on local events. Peripheral Via a catheter, neurotrophic agents of nitric oxide may result in arterial nerve regeneration following injury were delivered from an osmotic pump hypertension and atherosclerosis. is one process where events at the into the lumen of the nerve chamber. Abnormal nitric oxide levels can also injury site are critical to successful A second catheter functioned as a 180 regeneration. Recent publications vent to prevent pressure accumula- Day 17 (Before L-NAME treatment) in the neuroscience literature demon- tion. Using this device, Hekimian et Day 18 Day 22 strate techniques for targeting peri- al. confirmed that continuous four- 160 pheral nerves with neurotrophins. week delivery of drug solutions can Targeted delivery can also be used to be achieved in an environment which block nerve conductivity temporarily, is conducive to nerve regeneration. 140 a technique which may have utility The authors concluded that “the suc- in the study of neuromuscular devel- cess of this model opens the door for opment and reinnervation. a multitude of studies. With relative 120 ease, any stable solution can be Systolic Blood Pressure (mmHg) infused continuously into a nerve- A Novel Method for Targeting 1000 Peripheral Nerves guide chamber at a steady rate over Control 25 mg L-NAME 50 mg L-NAME a period of time.” 1 Several neurotrophic factors stimulate nerve regeneration in vitro, Figure 2: Changes in systolic blood pres- sure before L-NAME treatment (day 17), but these agents have proven difficult IGF-I Protects Against Diabetic Neuropathy after 1 day of treatment (day 18), and after to study in vivo. Hekimian et al. five days of treatment (day 22). Control from the Lahey Clinic developed a Neuropathy is a common compli- animals received saline. Changes in blood method for manipulating the nerve cation of diabetes. It is accompanied pressure after 25 mg and 50 mg L-NAME environment during regeneration.1 by impaired nerve regeneration in infusion were significantly different from This group constructed a chamber experimental diabetes, a condition controls (p < 0.01). to contain the distal and proximal associated with reduced levels of Reprinted with permission from Yallampalli C, Garfield RE. (Continued on Page 3, Column 1) AM J Obstet Gynecol 1993; 169:1316-1320. contribute to infection and inflam- mation, neurodegenerative Osmotic disorders, and the brain damage Pump Figure 1: Schematic diagram seen with stroke.1 of a nerve regeneration cham- ber. Drug solution from the Nitric Oxide Inhibition pump continuously bathes the Simulates Preeclampsia Inlet Catheter lumen of the nerve chamber, Exhaust Preeclampsia, or pregnancy- Catheter allowing the effect of neuro- trophic agents on nerve regen- induced hypertension, is a significant eration to be determined. health problem which affects up to Sciatic Nerve 30% of all women. It is the leading Nerve Guide Reprinted with permission from Hekimian cause of fetal growth retardation, Chamber KJ et al. J Reconstruct Microsurg 1995; 11(2):93-98. infant morbidity, and mortality asso- ciated with premature delivery and maternal death. Yallampalli and Garfield hypothesized that a causal factor in preeclampsia might be 1 (Continued on Page 4, Column 1) A L Z A Very Special Delivery Chronic Heavy For example, Cuevas et al. used basic Battler et al. also increased micro- fibroblast growth factor (bFGF), a vessel counts with bFGF in a porcine Metal Exposure peptide with a very short half-life, ischemia model.6 Stimulation of to induce angiogenesis in the arterial angiogenesis by locally-administered While the teratogenicity of cad- adventitia.1 Hayek et al. relied on bFGF bears promise for ischemic 2+ mium (Cd ) exposure has been well intrasplenic FGF infusion to promote disease treatment. documented, investigation into the the angiogenesis needed to maintain A wealth of knowledge about mechanism of action has been im- pancreatic islet grafts.2 Eppley et al. bFGF and other growth factors con- peded by difficulty in administering applied FGF directly to a bone graft 2+ tinues to accumulate as researchers precise amounts of Cd throughout to advance healing through angio- systematically deliver individual fac- gestation. Administration of cad- genesis.3 tors to various tissues. To draw upon mium in food or drinking water is More recently, Landau et al. published research in these areas, complicated by a lack of control over capitalized on bFGF’s angiogenic request an updated literature search dose. Gavage and injection offer enhancement of myocardial perfusion from ALZET Technical Services at greater control, but are stressful to in a rabbit model of ischemia.4 (800) 692-2990 or (415) 962-2251. animals, and hence can skew results. Increased coronary collateral vascu- Mahalik et al. used ALZET lature might rescue jeopardized pumps to surmount some of these tissue in conditions of decreased per- 1. Cuevas P, Gonzalez AM, Carceller F & Baird A. 2+ Circ Res 1991; 69:360-369. obstacles and to deliver Cd success- fusion. Landau et al. induced left 2. Hayek A, Lopez AD & Beattie GM. 1 fully to pregnant mice for 14 days. ventricular hypertrophy (LVH) by Transplantation 1990; 50(6):931-933. Their model resulted in a pattern of infusing intravenous angiotensin II 3. Eppley BL, Doucet M, Connolly DT, & Feder J. 2+ J Oral Maxillofac Surg 1988; 46:391-398. fetal anomalies and Cd distribution (AII). Rapidly-acquired LVH results 4. Landau C, Jacobs AK, & Haudenschild CC. which closely mirrored results in myocardial oxygen deficit due to Am Heart J 1995; 129:924-931. obtained using other dosing routes. 5. Yanagisawa-Miwa A, Uchida Y, Nakamura F, inadequate capillary density to sup- Tomaru T, Kido H, Kamijo T, Sugimoto T, Kaji Mahalik et al. stated that “chronic port hypertrophic muscle. Landau K, Utsuyama M, Kurashima C, & Ito H. Science teratogenic studies are often compli- et al. hoped to offset this deficit by 1992; 257:1401-1403. cated by the requirement for daily 6. Battler A, Scheinowitz M, Bor A, Hasdai D, stimulating new capillary formation. Vered Z, Segni E, Varda-Bloom N, Nass D, drug administration and animal After one week of AII treatment, Engelberg S, Eldar M, Belkin M & Savion N. handling, which have been shown to bFGF was infused by ALZET pump J Am Coll Cardiol 1993; 22:2001-2006. produce significant fetal and/or post- for 11 to 28 days via a catheter natal effects. The osmotic minipump advanced into the pericardial space provides a convenient and depend- using a transphrenic approach. able route of drug or toxicant admin- Controls received albumin in place istration that minimizes animal of bFGF or intravenous AII alone. Direct Delivery to the CNS handling and maternal stress. Non-ischemic controls received saline Surgical implantation of the pumps instead of AII. In a recently-published review, is also well-tolerated and does not Histological analysis of subepi- Theo Hagg provides a comprehensive typically cause infection or other cardial myocardium graded capillary protocol for the infusion of agents observable complications.” 1 For ref- density, ischemic necrosis, and fibro- into the brain using ALZET osmotic erences on using ALZET pumps to sis. Greater fibrosis in AII-treated pumps.1 Dr. Hagg outlines a variety administer cadmium and other heavy animals was consistent with microin- of procedures and recommendations, metals, contact ALZET Technical farcts resulting from LVH-induced including the construction of coiled Services at (800) 692-2990. oxygen deficit. Capillary density tubing to serve as an external reser- was increased markedly in animals voir, preparation of a dental acrylic 1. Mahalik MP, Hitner HW, and Prozialeck WC. platform for securing the cannula to Toxicol Letters 1995; 76:195-202. treated with both bFGF and AII, as compared with normal epicardial the skull, preimplantation advice, vascularity in animals receiving surgical tips, and post vivo analysis. Intrapericardial FGF AII alone. Hagg concludes that “the ALZET May Salvage Ischemic Myocardial angiogenesis has osmotic pump has clearly facilitated been demonstrated in other animal and expanded the possibilities of Myocardium models. Yanagisawa et al. produced experimental approaches in the a canine model of ischemia caused investigation of the CNS”.1 For a In numerous instances, by coronary artery stenosis and an copy of this review, contact ALZET researchers have used ingenious artificial thrombus.5 Slow injection Technical Services at (800) 692-2990 surgery and an ALZET pump to of bFGF after occlusion increased or at (415) 962-2251. deliver growth factors directly to a the number of capillaries and arteri- specific tissue. Targeted delivery 1. Hagg T. Continuous Central Nervous System oles versus controls. Left ventricular Infusion with ALZET Osmotic Pumps. In can avoid confusing or toxic systemic ejection fraction, a measure of car- Flanagan TR, Emerich DF, and Winn SR (eds). effects, while ensuring that the diac performance, decreased post- Methods in Neurosciences, Volume 21: growth factor reaches the target tis- Providing Pharmacological Access to the Brain: occlusion, but rebounded significant- Alternate Approaches. Academic Press, 1994, sue and is maintained there at suffi- ly after one week of bFGF treatment. pp. 201-213. cient concentration to exert its effects. 2 A L Z A During reinnervation, Barry and Ribchester blocked conduction in the 11 Figure 3: Effects of locally- sciatic nerve by infusing tetrodotoxin infused aFGF on motor axon Untreated Groups (TTX) via a silastic cuff connected to regeneration distance.
Load more

Recommended publications
  • Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease
    International Journal of Molecular Sciences Review Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease Michiel Van Bulck 1,2 , Ana Sierra-Magro 1,2, Jesus Alarcon-Gil 1, Ana Perez-Castillo 1,2 and Jose A. Morales-Garcia 1,2,3,* 1 Instituto de Investigaciones Biomédicas (CSIC-UAM), Arturo Duperier, 4. 28029 Madrid, Spain; [email protected] (M.V.B.); [email protected] (A.S.-M.); [email protected] (J.A.-G.); [email protected] (A.P.-C.) 2 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Valderrebollo, 5, 28031 Madrid, Spain 3 Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain * Correspondence: [email protected] Received: 31 December 2018; Accepted: 3 February 2019; Published: 8 February 2019 Abstract: Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer’s and Parkinson’s diseases. A progressive neurodegenerative process and neuroinflammation occur, and no current therapies can prevent, slow, or halt disease progression. To date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. Therefore, early diagnosis and the discovery of new targets and novel therapies are of upmost importance. Neurodegenerative diseases, like in other age-related disorders, the progression of pathology begins many years before the onset of symptoms. Many efforts in this field have led to the conclusion that exits some similar events among these diseases that can explain why the aging brain is so vulnerable to suffer neurodegenerative diseases.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • In Utero Exposure to Antidepressant Drugs and Risk of Attention Deficit Hyperactivity Disorder (ADHD)
    FACULTY OF HEALTH SCIENCE; AARHUS UNIVERSITY In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder (ADHD): A nationwide Danish cohort study Research year report Kristina Laugesen Department of Clinical Epidemiology, Aarhus University Hospital Supervisors Henrik Toft Sørensen, MD, PhD, DMSc, professor (main supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Morten Olsen, MD, PhD (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Ane Birgitte Telén Andersen, PhD-student, MPH (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Preface This study was carried out during my research year at Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (February 2012 - January 2013). I would like to express my gratefulness to my main supervisor Henrik Toft Sørensen and the Department of Clinical Epidemiology. This department contributes to research of high standard and I feel lucky to have been a part of the research environment here. From my point of view a research environment of high standard originates not only from bright and innovative people but also from the ability to work together, share knowledge and ideas and make use of people´s different skills, all qualities possessed by this department. Thank you for having introduced me to epidemiological research, I have definitely been encouraged to continue research in this field. Also I would like to say thank you for giving me the possibility to go to Boston for three months during my research year. It has been an experience of great personal and intellectual gain. A special thanks to Elizabeth Hatch who have warmly welcomed us at the Department of Public Health, Boston University.
    [Show full text]
  • Medical Guidelines Important Medical Precautions
    Safety at the Ceremonies & Medical Guidelines Important Medical Precautions Ricardo has many years of experience in holding medicine events and knows the safe use of Ayahuasca in its traditional context. Please note that in certain cases working with Ayahuasca can carry health risks: if you have any heart, liver or kidney, or other serious medical problems, you should inform us at the first opportunity, and discuss the issues with a doctor who is aware of the issues Ayahuasca may raise. Our priority is your safety and well-being, within the events guiding you to personal healing and growth. We will provide the most secure environment to work with Ayahuasca we possibly can, and will ensure your welfare as best we can at all time. In return we ask that you behave responsibly and do not endanger yourself or others. It is necessary that you agree to disclose, in confidence, any known medical conditions and/or use of any medication, at the time of booking. By coming to the medicine event, you are declaring that you are in a physical and mental condition appropriate to the activities described in the dietary and medical guidelines, and agree that you participate at your own risk and that we cannot accept liability for any accident or injury. Certain drugs and medications have been found to not be compatible with Ayahuasca. It is essential to stop taking the following substances, and give your system sufficient time to remove them from the body, before you begin a workshop. Please consult your doctor if you are in any doubt: you certainly should not suddenly stop taking prescribed medications (including antidepressants) without consulting your doctor.
    [Show full text]
  • Synthesis of Enantioenriched Piperidine-Based, Spirocyclic Analogues of AF64A and Acetylcholine
    Loyola University Chicago Loyola eCommons Dissertations Theses and Dissertations 1994 Synthesis of Enantioenriched Piperidine-Based, Spirocyclic Analogues of AF64A and Acetylcholine Nam Huh Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_diss Part of the Chemistry Commons Recommended Citation Huh, Nam, "Synthesis of Enantioenriched Piperidine-Based, Spirocyclic Analogues of AF64A and Acetylcholine" (1994). Dissertations. 3465. https://ecommons.luc.edu/luc_diss/3465 This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 1994 Nam Huh LOYOLA UNIVERSITY OF CIDCAGO SYNTHESIS OF ENANTIOENRICHED PIPERIDINE-BASED, SPIROCYCLIC ANALOGUES OF AF64A AND ACETYLCHOLINE A DISSERTATION SUBMITI'ED TO THE FACULTY OF THE GRADUATE SCHOOL IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF CHEMISTRY BY NAM HUH CHICAGO, IL MAY 1994 Copyright by Nam Huh, 1994 All rights reserved 11 ACKNOWLEDGEMENT The author wishes to express his deepest gratitude to Dr. Charles M. Thompson for his persistent motivation, his continual support, and his friendship; all of which made this work possible. Thanks are expressed to the members of the Dissertation Committee: Dr. Leslie W. M. Fung, Dr. David S. Crumrine, and Prof. Israel Hanin, for their willingness to serve in this capacity. The author would also like to thank all of the Organic Division students, especially those in the "Thompson Group", who made life on the second floor endurable.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Alaproclate (hydrochloride) Item No. 27770 CAS Registry No.: 60719-83-7 Formal Name: alanine, 2-(4-chlorophenyl)-1,1- dimethylethyl ester, monohydrochloride NH Synonyms: GEA 654, A03 2 MF: C13H18ClNO2 • HCl O FW: 292.2 Purity: ≥95% O UV/Vis.: λmax: 222 nm Cl • HCl Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Alaproclate (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the alaproclate (hydrochloride) in water. We do not recommend storing the aqueous solution for more than one day. Description Alaproclate is a selective serotonin reuptake inhibitor (SSRI).1,2 It inhibits depletion of serotonin (5-HT) induced by 4-methyl-α-ethyl-m-tyramine in rat cerebral cortex, hippocampus, hypothalamus, 1 and striatum (EC50s = 18, 4, 8, and 12 mg/kg, respectively). Alaproclate inhibits NMDA-evoked currents and depolarization-induced voltage-dependent potassium currents in rat hippocampal neurons (IC50s = 1.1 and 6.9 μM, respectively) and does not inhibit GABA-evoked currents when used at concentrations up to 100 μM.2 It increases sirtuin 1 (SIRT1) levels in N2a murine neuroblastoma cells expressing apolipoprotein E4 (ApoE4; IC50 = 2.3 μM) and in the hippocampus in the FXFAD-ApoE4 transgenic mouse model of Alzheimer’s disease when administered at a dose of 20 mg/kg twice daily.3 Alaproclate (40 mg/kg) decreases immobility time in the forced swim test in rats, indicating antidepressant- like activity.4 References 1.
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • Basic and Clinical Aspects of Depression
    Abstracts of Poster Presentations 259 31.01.01 PHARMACOTHERAPY, PSYCHOTHERAPY, AND PSYCHOEDUCATIONAL INTERVENTIONS: EFFICACY IN RECURRENT DEPRESSION POSTER E. Frank, and D. J. Kupfer We are currently engaged in a study of maintenance treatments for PRESENTATION recurrent unipolar depression which compares the efficacy of psychotherapy, pharmacotherapy and their combination. Rather 31.01 than focusing exclusively on the number of recurrences in each of the experimental conditions, we have also been concerned with the quality of patients' lives between episodes and with the !ength of the symptom-free interval. The three-year maintenance phase of our study is still in progress; therefore, final results will not be available for another 18 months to 2 years. We can, however, discuss the information available on Basic and Clinical Aspects those 62 patients who have already experienced a recurrence of illness and for whom the blind has been broken. While the majority of Depression of recurrences have been experienced by patients in the non- medication conditions, it would appear that, with or without medication, psychotherapy has had a significant effect in delaying the onset of a new episode. At this point in time, however, we have little evidence that continued psychotherapy adds to the generally good quality of patients' social functioning in symptom-free interval. A full understanding of the additive and interactive effects of pharmacotherapy and psychotherapy in the treatment of recurrent depression must await the completion of this study
    [Show full text]
  • Antidepressant Treatment for Postnatal Depression
    This is a repository copy of Antidepressant treatment for postnatal depression. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/163986/ Version: Published Version Article: Brown, Jennifer Valeska Elli orcid.org/0000-0003-0943-5177, Wilson, Claire A., Ayre, Karyn et al. (5 more authors) (2020) Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews. CD013560. ISSN 1469-493X https://doi.org/10.1002/14651858.CD013560 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Library Cochrane Database of Systematic Reviews Antidepressant treatment for postnatal depression (Protocol) Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H. Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD013560. DOI: 10.1002/14651858.CD013560. www.cochranelibrary.com Antidepressant treatment for postnatal depression (Protocol) Copyright © 2020 The Cochrane Collaboration.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/20 (2006.01) A61K 31/485 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2013/06385 1 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, 1 July 20 13 (01 .07.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2012 70405 6 July 2012 (06.07.2012) DK (84) Designated States (unless otherwise indicated, for every 61/668,741 6 July 2012 (06.07.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: EGALET LTD.
    [Show full text]